

AA

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number  
WO 01/59063 A2

(51) International Patent Classification <sup>7</sup> :	C12N	60/226,868	22 August 2000 (22.08.2000)	US
(21) International Application Number:	PCT/US01/01334	60/227,182	22 August 2000 (22.08.2000)	US
(22) International Filing Date:	17 January 2001 (17.01.2001)	60/226,681	22 August 2000 (22.08.2000)	US
(25) Filing Language:	English	60/227,009	23 August 2000 (23.08.2000)	US
(26) Publication Language:	English	60/228,924	30 August 2000 (30.08.2000)	US
(30) Priority Data:		60/229,344	1 September 2000 (01.09.2000)	US
60/179,065	31 January 2000 (31.01.2000)	US	60/229,343	1 September 2000 (01.09.2000)
60/180,628	4 February 2000 (04.02.2000)	US	60/229,287	1 September 2000 (01.09.2000)
60/184,664	24 February 2000 (24.02.2000)	US	60/229,345	1 September 2000 (01.09.2000)
60/186,350	2 March 2000 (02.03.2000)	US	60/229,513	5 September 2000 (05.09.2000)
60/189,874	16 March 2000 (16.03.2000)	US	60/229,509	5 September 2000 (05.09.2000)
60/190,076	17 March 2000 (17.03.2000)	US	60/230,438	6 September 2000 (06.09.2000)
60/198,123	18 April 2000 (18.04.2000)	US	60/230,437	6 September 2000 (06.09.2000)
60/205,515	19 May 2000 (19.05.2000)	US	60/231,413	8 September 2000 (08.09.2000)
60/209,467	7 June 2000 (07.06.2000)	US	60/232,080	8 September 2000 (08.09.2000)
60/214,886	28 June 2000 (28.06.2000)	US	60/231,414	8 September 2000 (08.09.2000)
60/215,135	30 June 2000 (30.06.2000)	US	60/231,244	8 September 2000 (08.09.2000)
60/216,647	7 July 2000 (07.07.2000)	US	60/232,081	8 September 2000 (08.09.2000)
60/216,880	7 July 2000 (07.07.2000)	US	60/231,242	8 September 2000 (08.09.2000)
60/217,487	11 July 2000 (11.07.2000)	US	60/231,243	8 September 2000 (08.09.2000)
60/217,496	11 July 2000 (11.07.2000)	US	60/231,968	12 September 2000 (12.09.2000)
60/218,290	14 July 2000 (14.07.2000)	US	60/232,401	14 September 2000 (14.09.2000)
60/220,963	26 July 2000 (26.07.2000)	US	60/232,399	14 September 2000 (14.09.2000)
60/220,964	26 July 2000 (26.07.2000)	US	60/232,400	14 September 2000 (14.09.2000)
60/225,757	14 August 2000 (14.08.2000)	US	60/232,397	14 September 2000 (14.09.2000)
60/225,270	14 August 2000 (14.08.2000)	US	60/233,063	14 September 2000 (14.09.2000)
60/225,447	14 August 2000 (14.08.2000)	US	60/233,064	14 September 2000 (14.09.2000)
60/225,267	14 August 2000 (14.08.2000)	US	60/233,065	14 September 2000 (14.09.2000)
60/225,758	14 August 2000 (14.08.2000)	US	60/232,398	14 September 2000 (14.09.2000)
60/225,268	14 August 2000 (14.08.2000)	US	60/234,223	21 September 2000 (21.09.2000)
60/224,518	14 August 2000 (14.08.2000)	US	60/234,274	21 September 2000 (21.09.2000)
60/224,519	14 August 2000 (14.08.2000)	US	60/234,997	25 September 2000 (25.09.2000)
60/225,759	14 August 2000 (14.08.2000)	US	60/234,998	25 September 2000 (25.09.2000)
60/225,213	14 August 2000 (14.08.2000)	US	60/235,484	26 September 2000 (26.09.2000)
60/225,266	14 August 2000 (14.08.2000)	US	60/235,834	27 September 2000 (27.09.2000)
60/225,214	14 August 2000 (14.08.2000)	US	60/235,836	27 September 2000 (27.09.2000)
60/226,279	18 August 2000 (18.08.2000)	US	60/236,369	29 September 2000 (29.09.2000)
			60/236,327	29 September 2000 (29.09.2000)
			60/236,370	29 September 2000 (29.09.2000)
			60/236,368	29 September 2000 (29.09.2000)
			60/236,367	29 September 2000 (29.09.2000)

[Continued on next page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel nervous system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "nervous system antigens", and the use of such nervous system antigens for detecting disorders of the nervous system, particularly the presence of cancers of the nervous system and nervous system cancer metastases. More specifically, isolated nervous system associated nucleic acid molecules are provided encoding novel nervous system associated polypeptides. Novel nervous system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human nervous system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the nervous system, including cancers of the nervous system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

WO 01/59063 A2



60/237,039	2 October 2000 (02.10.2000)	US	60/251,030	5 December 2000 (05.12.2000)	US
60/237,038	2 October 2000 (02.10.2000)	US	60/251,988	5 December 2000 (05.12.2000)	US
60/237,040	2 October 2000 (02.10.2000)	US	60/256,719	5 December 2000 (05.12.2000)	US
60/237,037	2 October 2000 (02.10.2000)	US	60/251,479	6 December 2000 (06.12.2000)	US
60/236,802	2 October 2000 (02.10.2000)	US	60/251,869	8 December 2000 (08.12.2000)	US
60/239,937	13 October 2000 (13.10.2000)	US	60/251,856	8 December 2000 (08.12.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US	60/251,868	8 December 2000 (08.12.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US	60/251,990	8 December 2000 (08.12.2000)	US
60/241,809	20 October 2000 (20.10.2000)	US	60/251,989	8 December 2000 (08.12.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US	60/254,097	11 December 2000 (11.12.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US	60/259,678	5 January 2001 (05.01.2001)	US
60/241,808	20 October 2000 (20.10.2000)	US			
60/242,221	20 October 2000 (20.10.2000)	US			
60/241,786	20 October 2000 (20.10.2000)	US			
60/241,826	20 October 2000 (20.10.2000)	US			
60/244,617	1 November 2000 (01.11.2000)	US			
60/246,474	8 November 2000 (08.11.2000)	US			
60/246,532	8 November 2000 (08.11.2000)	US			
60/246,476	8 November 2000 (08.11.2000)	US			
60/246,475	8 November 2000 (08.11.2000)	US			
60/246,526	8 November 2000 (08.11.2000)	US			
60/246,525	8 November 2000 (08.11.2000)	US			
60/246,528	8 November 2000 (08.11.2000)	US			
60/246,477	8 November 2000 (08.11.2000)	US			
60/246,611	8 November 2000 (08.11.2000)	US			
60/246,610	8 November 2000 (08.11.2000)	US			
60/246,613	8 November 2000 (08.11.2000)	US			
60/246,609	8 November 2000 (08.11.2000)	US			
60/246,478	8 November 2000 (08.11.2000)	US			
60/246,524	8 November 2000 (08.11.2000)	US			
60/246,523	8 November 2000 (08.11.2000)	US			
60/246,527	8 November 2000 (08.11.2000)	US			
60/249,299	17 November 2000 (17.11.2000)	US			
60/249,210	17 November 2000 (17.11.2000)	US			
60/249,216	17 November 2000 (17.11.2000)	US			
60/249,217	17 November 2000 (17.11.2000)	US			
60/249,211	17 November 2000 (17.11.2000)	US			
60/249,215	17 November 2000 (17.11.2000)	US			
60/249,218	17 November 2000 (17.11.2000)	US			
60/249,208	17 November 2000 (17.11.2000)	US			
60/249,213	17 November 2000 (17.11.2000)	US			
60/249,212	17 November 2000 (17.11.2000)	US			
60/249,207	17 November 2000 (17.11.2000)	US			
60/249,245	17 November 2000 (17.11.2000)	US			
60/249,244	17 November 2000 (17.11.2000)	US			
60/249,297	17 November 2000 (17.11.2000)	US			
60/249,214	17 November 2000 (17.11.2000)	US			
60/249,264	17 November 2000 (17.11.2000)	US			
60/249,209	17 November 2000 (17.11.2000)	US			
60/249,300	17 November 2000 (17.11.2000)	US			
60/249,265	17 November 2000 (17.11.2000)	US			
60/251,160	1 December 2000 (01.12.2000)	US			
60/250,391	1 December 2000 (01.12.2000)	US			

(71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Lane, Laytonville, MD 20882 (US). **BARASH, Steven, C.** [US/US]; 111 Watkins Pond Blvd., #301, Rockville, MD 20850 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).

(74) Agents: **HOOVER, Kenley, K.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**ATCC Deposit No.:** 209059, 209060, 209061, 209062, 209063, 209064, 209065, 209066, 209067, 209068, 209069, 209579, 209578, 203067, 203068, 203609, 203610, 203485, PTA-252, PTA-253, PTA-1081, PTA-2574, PTA-2575, TS-1, TS-2, AC-1, AC-2

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

#### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

#### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

#### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence contained in Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide fragment of a polypeptide encoded by SEQ ID NO:X or a polypeptide fragment encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X;

(f) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(g) a polynucleotide which is a variant of SEQ ID NO:X;

(h) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(i) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence contained in cDNA Clone ID NO:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;

(e) a full length protein of SEQ ID NO:Y or the encoded sequence contained in cDNA Clone ID NO:Z;

(f) a variant of SEQ ID NO:Y;

(g) an allelic variant of SEQ ID NO:Y; or

(h) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

24. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

**THIS PAGE BLANK (USPTO)**